+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Mechanism of action of Roter (bismuth subnitrate) in patients with duodenal ulcer disease and healthy volunteers

Mechanism of action of Roter (bismuth subnitrate) in patients with duodenal ulcer disease and healthy volunteers

Journal of Gastroenterology and Hepatology 5(4): 382-386

The effects of Roter (compound bismuth subnitrate) on antacid activity and mucosal prostaglandin E2 (PGE2) synthesis were variously investigated in patients with duodenal ulcer disease and healthy volunteers. Roter had a significant but small antacid activity with a buffering capacity of 10.9 mmol per tablet. In healthy volunteers, this was assessed by 24 h gastric pH monitoring on matched days with and without Roter treatment. The percentage of time that gastric pH was above 3 and the time after a standard meal that the pH was above 3, were both significantly increased by treatment with Roter (II tds post-cibal) (P less than 0.01). Endogenous PGE2 synthesis was measured in endoscopic duodenal biopsies taken both before and after Roter treatment in patients with acute untreated duodenal ulceration. There was a significant deficiency of mucosal PGE2 synthesis in untreated patients compared with controls (P less than 0.005). However, following 4 weeks' treatment with Roter, there was a 90% rate of healing accompanied by a significant increase in PGE2 synthesis (P less than 0.05) up to control levels. These findings suggest that Roter heals by the combined effects of a modest antacid neutralizing capacity and the ability to restore mucosal prostaglandins to normal levels, thereby mediating prostaglandin-dependent defence mechanisms.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 040657237

Download citation: RISBibTeXText

PMID: 2129809

DOI: 10.1111/j.1440-1746.1990.tb01413.x

Related references

A double-blind, endoscopically assessed evaluation of a bismuth subnitrate preparation (Roter) and cimetidine in the treatment of duodenal ulcer. British Journal of Clinical Practice 40(9): 373-375, 1986

Clinical, radiological and laboratory findings in patients with duodenal ulcer, treated with micronized bismuth subnitrate, singly and in combination with antacids. British Journal of Clinical Practice 29(9): 227-233, 1975

Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease. Hepato-Gastroenterology 41(1): 43-47, 1994

Endogenous prostaglandin E2 synthesis preserved following cytoprotection by Roter (bismuth subnitrate) in the rat alcohol model of gastric ulceration. British Journal of Experimental Pathology 69(6): 833-838, 1988

Comparative action of the protective effects of various forms of bismuth subnitrate (colloidal and ordinary) in experimental gastric ulcer of the rat. Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales 150(5): 1019-1021, 1956

Gastric secretory and motor inhibition induced by certain methyl analogues of prostaglandin E2 in healthy male volunteers and in patients with duodenal ulcer disease. Advances in Prostaglandin and Thromboxane Research 2: 521-528, 1976

Comparison of the effects of gastric antisecretory agents in healthy volunteers and patients with duodenal ulcer. Gut 27(9): 1058-1061, 1986

Diurnal variation in pharmacokinetics and pharmacodynamics of nizatidine in healthy volunteers and in patients with duodenal ulcer. Gastroenterology 108(4 Suppl. ): A156, 1995

Assessment of the efficacy of de-nol and bismuth subnitrate treatment of patients with associated peptic ulcer and pyloric Helicobacter infection (experimental and clinical studies). Terapevticheskii Arkhiv 63(2): 21-26, 1991

Cyclic AMP and gastric secretion in man. An in vivo study in healthy volunteers, duodenal ulcer patients, and pernicious anaemia patients. Scandinavian Journal of Gastroenterology 23(9): 1025-1034, 1988

Bismuth preparations in the treatment of patients with gastric and duodenal ulcer disease. Klinicheskaia Meditsina 86(9): 57-63, 2008

Effect of intermittent administration of omeprazole on serum pepsinogens in duodenal ulcer patients and healthy volunteers. British Journal of Clinical Pharmacology 29(4): 465-472, 1990

Stimulation of gastric acid secretion by intravenous amino acids in healthy volunteers and duodenal ulcer patients. Stelzner, F (Ed ) Chirurgisches Forum Fuer Experimentelle Und Klinische Forschung, Vol 102 Kongress Der Deutschen Gesellschaft Fuer Chirurgie Muenchen, 10 -13 April (Surgical Forum For Experimental And Clinical Research, Vol 102nd Congress Of The German Society For Surgery, Munich, West Germany, Apr 10-13, ) Xxiii+339p Springer-Verlag: Berlin, West Germany; New York, N Y , Usa Illus Paper 285-290, 1985

Alleviation of cisplatin toxicity by high-dose bismuth subnitrate and pharmacokinetics of bismuth subnitrate and cisplatin. Nihon Gan Chiryo Gakkai Shi 25(6): 1138-1145, 1990

Night time famotidine 40 mg is equivalent to ranitidine 300 mg in 24 hour intragastric ph in non smoking healthy male volunteers with duodenal ulcer disease. Clinical and Investigative Medicine 11(4 Suppl.): C44, 1988